Ovarian tumours: Difference between revisions
Jump to navigation
Jump to search
| (One intermediate revision by the same user not shown) | |||
| Line 22: | Line 22: | ||
#*Significant findings: multilocular cyst, solid component, bilateral lesions, ascites, suspected intra-abdominal [[metastases]] (one finding=1 point, two or more findings=4 points). | #*Significant findings: multilocular cyst, solid component, bilateral lesions, ascites, suspected intra-abdominal [[metastases]] (one finding=1 point, two or more findings=4 points). | ||
#Menopause/pre-menopause status (menopausal=4 points, pre-menopausal=1 point). | #Menopause/pre-menopause status (menopausal=4 points, pre-menopausal=1 point). | ||
#CA-125 (blood test) in ''U/ml''. | #[[CA-125]] (blood test) in ''U/ml''. | ||
====Interpretation==== | ====Interpretation==== | ||
| Line 322: | Line 322: | ||
===Classification=== | ===Classification=== | ||
*Benign. (Dx: mucinous cystadenoma ''or'' mucinous adenofibroma ''or'' mucinous cystadenofibroma) | *Benign. (Dx: [[Mucinous_cystadenoma_of_the_ovary|mucinous cystadenoma]] ''or'' mucinous adenofibroma ''or'' mucinous cystadenofibroma) | ||
**Single layer of cells. | **Single layer of cells. | ||
*Borderline. (Dx: ''mucinous tumour of uncertain malignant potential'' or ''borderline mucinous tumour'') | *Borderline. (Dx: ''mucinous tumour of uncertain malignant potential'' or ''borderline mucinous tumour'') | ||